Having suffered a setback in the summer with its AstraZeneca PLC-partnered asset monalizumab, there is a lot riding on Innate Pharma S.A.'s lacutamab and initial mid-stage data on the French biotech's drug have proved promising.
The Marseille-headquartered group has presented data in the ongoing Phase II TELLOMAK trial at the European Organisation for Research and...